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Abstract
Introduction. Obesity among young people has increased dramatically worldwide, and the prevalence continues to 
increase. Studies performed in both adults and children have confirmed that abnormalities of cardiac function and 
autonomic nervous system are present in those with obesity and might explain at least in part the increased mortality 
seen in those with obesity.
Materials and methods. The present study explores hemodynamic, autonomic and cardiovascular function in a cohort 
of well-characterized young men with obesity and compared these measures to those from a cohort of men of compa-
rable age without obesity. Subjects underwent examination using Task Force® Monitor non-invasive assessment of the 
cardiovascular functions.
Results. The obesity group had a significantly higher resting heart rate (74.3 ± 11.8 vs. 56.0 ± 8.9 n/min, p < 0.0001), 
systolic (128.1 ± 9.4 vs. 114.3 ± 7.0 mm Hg, p < 0.0001) and diastolic (85.1 ± 8.2 vs. 70.7 ± 6.2 mm Hg, p < 0.0001) 
blood pressure compared to the age- and sex-matched, non-obesity group. This was coupled with significantly reduced 
stroke volume (81.3 ± 22.7 vs. 112.8 ± 20.3 ml, p < 0.0001), cardiac output (5.9 ± 1.5 vs. 6.2 ± 1.4 l/min; p < 0.0001) 
thoracic fluid content (28.5 ± 3.3 vs. 36.0 ± 3.3 1/Ohm, p < 0.0001) and contractility parameters, index of contractility 
(31.7 ± 12.9 vs. 68.8 ± 16.1 1000/s, p < 0.0001) and Heather index (0.1 ± 0.0 vs. 0.3 ± 0.0 1/s2, p < 0.0001).
Discussion. Our results confirm that obesity is associated with sub-clinical and cardiovascular abnormalities that can 
be identified using non-invasive measures. The differences identified in those with obesity were in young and healthy 
individuals. It will be important to determine whether these findings can be used to predict future clinical abnormalities.
Key words: obesity, functionally single ventricle, Fontan procedure, congenital heart disease, tissue Doppler imaging, 
echocardiography
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Introduction
Obesity is a disease process, characterized by abnormal or 
excessive fat accumulation that presents a risk to health, 
typically considered as an imbalance between energy pro-
vision and expenditure or between intake of calories and 
physical activity [1–6].
The prevalence of obesity (body mass index [BMI] ≥ 
≥ 30 kg/m2) has increased dramatically worldwide. In 
Europe, the prevalence of obesity increases with age to 
peak at approximately 60 years. Childhood obesity is also 
becoming a major public health problem. The World Health 
Organization (WHO) has recognized obesity, as a global 
epidemic, which is representing a rapidly growing threat 
to the health of populations in an increasing number of 
countries. WHO suggests that at least 2.8 million people 
die each year as a consequence of obesity [1–6].
People with obesity are at a higher risk of significant 
medical conditions such as: diabetes, cardiovascular 
disease (hypertension, stroke, heart disease), sleep apnea 
and some cancers (including: pancreatic, renal, bladder, 
uterine cervical and prostate cancers) [7, 8].
Studies performed in both adults and children have con-
firmed that abnormalities of the autonomic nervous system 
are present in those with obesity and might explain at least 
in part the increased mortality seen in those with obesity. 
Obesity can affect the cardiovascular system in several 
ways, with hypertension being one of the most important 
adverse processes. The mechanisms underlying hyperten-
sion in people with obesity are not fully understood, but 
there is increasing evidence that obesity may provide the 
trigger for sympathetic nervous system activation as well 
as for changes in renal structure and function. Renal dys-
function plays a key role in increasing blood pressure and it 
is closely related to the renin-angiotensin and sympathetic 
nervous system [9, 10].
This study explores the hemodynamic, autonomic and 
cardiovascular function with those from a cohort of men 
of comparable age without obesity. The aim of the study 
was to objectively verify whether the presence of obesity is 
associated with sub-clinical changes in autonomic cardio-
vascular functions which occur in young obese subjects, 




The present study was carried out on 35 volunteers, of 
whom 15 were young men with obesity and 20 were young 
male controls without obesity. Subjects were categorized as 
normal obese using BMI [(BMI) weight (kg)/height (m)2]. No 
subjects were taking vasoactive medication, which could 
affect cardiovascular parameters and none had a history of 
diabetes, hypertension, hormonal disturbances, cardiovas-
cular disease or neurological illness. Subjects underwent 
a comprehensive cardiac and neurologic clinical and 
diagnostic work-up prior to inclusion in the present study in 
order to rule out any abnormality of both the cardiovascular 
function and the autonomic nervous system.
In our study we investigated participants which fulfilled 
precise inclusion criteria. The examined group was distin-
guished on the base of medical and subjective examination. 
Body weight, BMI, and body composition were measured. 
Persons participating in the examination did not require 
the chronic treatment.
Data on lifestyle habits (smoking status, physical acti-
vity and alcohol intake), body weight, body height, waist 
and hip circumferences were measured using standar-
dized protocols. This study examined a group of drinking 
no alcohol and never-smokers, who reported no regular 
physical activity. The obesity group and control group did 
not undergo any dietary restrictions.
Setting
The study was conducted in the Laboratory of Chrono-
medicine and Functional Examination of the Autonomic 
Nervous System (Department of Hygiene and Epidemiology, 
Department of Human Physiology), Collegium Medicum 
NCU, Bydgoszcz, Poland. The examination took place using 
our standard functional examination of the autonomic 
nervous conditions. Prior to the test, the patient rested for 
15 minutes in a supine position. During the examination, 
room temperature was approximately 21°C and the room 
was quiet and darkened. The whole procedure was conduc-
ted according to the American Academy of Neurology and 
European Heart Association guidelines [11–13]. The study 
was approved by the Human Research Committee of the 
Nicolas Copernicus University in Torun. Written informed 
consent was signed by all subjects.
Measurement of cardiac hemodynamic  
and autonomic regulation
The subjects underwent examination using Task Force® 
Monitor (TFM — CNSystems, Medizintechnik, Gratz, Austria), 
a specialist device for non-invasive examination of the 
cardiovascular system and functional assessment of the 
autonomic nervous system. TFM includes the following com-
ponents: digital photoplethysmography for the continuous 
measurement of blood pressure, electrocardiograph (ECG), 
impedance cardiograph (ICG), and oscillometric measure-
ment of blood pressure. All parameters were collected in 
the non-invasive beat-to-beat mode.
The device for the continuous measurement of blood 
pressure determines the pressure of perivascular environ-
ment in the distal part of upper limb. In the case of TFM, the 
measurements are obtained with controlled pressure air cuff 
and plethysmograph, placed on the middle and index fingers.
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Electrocardiograph registers the electrical activity of the 
myocardium detected as the voltage difference between 
two electrodes at the surface of the chest, and presents it 
graphically as the electrocardiographic curve.
Impedance cardiograph analyzes the components 
of impedance signal registered in the chest during one 
cardiac cycle.
The device for the oscillometric measurement of blood 
pressure senses the magnitude of oscillations caused by the 
blood flowing into the arm compressed with occluding cuff.
The last component of TFM system is pulse oximeter, 
monitoring the oxygen saturation of patient’s blood.
The TFM obtains biological signals non-invasively and 
thus all of the procedures are safe for the participants of 
this study. The “beat to beat” measurements enable deter-
mination of arterial blood pressure, stroke volume, minute 
volume, peripheral resistance, heart rate variability (HRV), 
blood pressure variability (BPV), and spontaneous barore-
ceptor sensitivity. The autonomic function (HRV and BPV) is 
assessed by means of spectral analysis, while baroreceptor 
sensitivity (BR) is analyzed with the sequential method.
Data analysis
Data are presented as mean with the standard deviation. 
Group-wise comparison was performed with Student’s t-
-test and linear relationships with Pearson’s r. Statistical 
significance was set at < 0.05. Based on the correlation 
between the data and the corresponding normal scores, 
we used The Shapiro-Wilk test — the best choice for testing 
the normality of data. Linear regression models were built 
as theoretical models, containing those cardiovascular 
variables which would be expected to have an influence on 
the dependent outcome; as age can also influence autono-
mic function it was also included. Variables were excluded 
if they exceeded the tolerance level for multicollinearity. 
Analysis was performed with SPSS and Statistica.
Results
Details of the study group (with obesity) and control (without 
obesity) group are shown in Table 1. The obesity group 
had a significantly higher resting heart rate, systolic and 
diastolic blood pressure compared with the non-obesity 
group (Table 2). This was coupled with significantly reduced 
stroke volume (SV) that persisted, when the body surface 
area (BSA) was considered — the stroke index (SI). Cardiac 
output (CO) between the groups was not significantly diffe-
rent until it was corrected for BSA (the cardiac index), upon 
which the obesity group had a significantly reduced cardiac 
output compared with controls. Total peripheral resistance 
index (TPRI, corrected for BSA) was significantly increased 
in the obesity group compared with the controls (Table 2), 
whereas the preload (end diastolic index normalized for 
BSA) was significantly lower in the obesity group.
On comparing cardiac function and myocardial con-
tractility between the two groups, all measures were 
lower in the obesity group with the index of contractility 
(IC — maximum blood flow during left ventricular ejection), 
acceleration index (ACI — the left ventricular–aortic systolic 
jet acceleration) and Heather’s index (HI — a measure of 
positive inotropy of heart muscle) being significantly sta-
tistically lower. Interestingly, the parameters that might 
indicate heart failure, specifically systolic time ratio (STR) 
and left ventricular work index (LVWI) were not significantly 
different between the obesity group and controls. Alongside 
these cardiac changes was a significantly lowered thoracic 
fluid content (TFC) in the obesity group and this level was 
lower than the expected minimum value in the physiological 
conditions at this age.
The correlations between BMI and cardiovascular para-
meters are shown in Table 3. Among the cardioimpedance 
parameters, BMI correlated inversely with all contractility 
parameters and thoracic fluid content. In keeping with the 
higher mean ejection rate (ER) in the group comparison, 
there was a significantly positive correlation with ER and 
the BMI.
Linear regression models were constructed to identify 
whether BMI was independently associated with cardiac 
function. Controlling for age and the hemodynamic pa-
rameters measured, linear regression demonstrated an 
independent association between BMI and cardiac index, 
such that as BMI increased there was a reduction in the 
cardiac index — adjRsq 0.857, beta –0.037 (95% confiden-
ce interval [CI] –0.058 to –0.017), p = 0.001. In addition, 
Table 1. Details of the two groups of participants: age, weight, height and body mass index (BMI)





Age [years] 36.3 ± 7.3 33.7 ± 6.2 0.3
Weight [kg] 116.2 ± 17.6 75.4 ± 7.1 < 0.0001*
Height [m] 1.79 ± 0.07 1.7 ± 0.05 0.8
BMI [kg/m2] 36.4 ± 5.0 23.4 ± 1.3 < 0.0001*
*Indicates significantly different results; all parameters are expressed as mean ± standard deviation, and p values
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BMI was associated with the IC, such that an increase in 
BMI was independently associated with a reduction in 
contractility of the heart — adjRsq 0.85, beta –0.847 (95% 
CI –1.592 to –0.101), p = 0.027.
Discussion
The results reported here confirm that there are significant 
cardiac abnormalities in young men with obesity compared 
with young men without obesity. Both measurements of 
cardiovascular hemodynamic and cardiac function were 
noted to be significantly different in those with obesity. 
These differences appear to be related to peripheral arterial 
abnormalities and significantly reduced cardiac inotropy. 
Those with obesity had significantly greater mean arterial 
blood pressure and a significantly reduced cardiac index 
which indicates that they have a reduced cardiac inotropy 
and an increase in vasoconstriction compared with controls 
(Fig. 1) [14]. Demonstrating these findings is of importance 
for two reasons. Firstly, obesity is now considered a global 
epidemic and as such, these results will be far reaching. 
Secondly, all the subjects in this study were young, healthy 
males with no clinical history of cardiac or vascular disease. 
Despite this, those with obesity demonstrated significant 
cardiac and cardiovascular differences when compared 
with those without obesity. These sub-clinical abnorma-
lities may represent precursors to the increased risk of 
cardiovascular disease seen in people with obesity but may 
also contribute to the as yet unexplained increased risk of 
sudden cardiac death in young with obesity.
It is well known that obesity has a major impact on 
cardiovascular diseases, such as heart failure, coronary 
heart disease, atrial fibrillation and sudden cardiac death 
[15–18]. Studies suggest that obesity can exacerbate 
cardiovascular disease through a variety of mechanisms 
including activation of the sympathetic nervous system 
Table 3. Matrix of correlations between body mass index (BMI) 
and cardiac functions: index of contractility (IC), acceleration 
index (ACI), Heather index (HI), diastolic index (EDI), systolic time 
ratio (STR), ejection rate (ER), left ventricular work index (LVWI) 
and thoracic fluid content: thoracic fluid content (TFC), significant 
correlations in bold, and p values
Parameter BMI p
IC [1000/s] –0.70 < 0.05
ACI [100/s2] –0.64 < 0.05
HI [1/s2] –0.65 < 0.05
EDI [ml/m2] –0.64 < 0.05
STR [%] 0.24 > 0.05
ER [%] 0.48 < 0.05
LVWI [mm Hg × l/(min × m2)] –0.15 > 0.05
TFC (1/Ohm) –0.74 < 0.05
Table 2. Hemodynamic and cardiovascular parameters: heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), 
stroke volume (SV), stroke index (SI), diastolic index (EDI), cardiac output (CO), cardiac index (CI), total peripheral resistance index (TPRI), 
index of contractility (IC), acceleration index (ACI), Heather index (HI), systolic time ratio (STR), ejection rate (ER), left ventricular work in-
dex (LVWI), thoracic fluid content (TFC); at rest in the two groups of participants 
Parameter Obesity group Non-obesity group p
HR [n/1] 74.3 ± 11.8 56.0 ± 8.9 < 0.0001*
SBP [mm Hg] 128.1 ± 9.4 114.3 ± 7.0 < 0.0001*
DBP [mm Hg] 85.1 ± 8.2 70.7 ± 6.2 < 0.0001*
SV [ml] 81.3 ± 22.7 112.8 ± 20.3 < 0.0001*
SI [ml/m2] 35.3 ± 10.2 58.3 ± 10.1 < 0.0001*
EDI [ml/m2] 58.1 ± 14.4 94.5 ± 16.4 < 0.0001*
CO [l/min] 5.9 ± 1.5 6.2 ± 1.4 0.4971
CI [l/min/m2] 2.5 ± 0.6 3.2 ± 0.7 0.0095*
TPRI [dyn × s × m2/cm5] 3181 ± 833.0 2158.4 ± 492.5 < 0.0001*
IC [1000/s] 31.7 ± 12.9 68.8 ± 16.1 < 0.0001*
ACI [100/s2] 46.8 ± 18.8 95.1 ± 24.4 < 0.0001*
HI [1/ s2] 0.1 ± 0.0 0.3 ± 0.0 < 0.0001*
STR [%] 37.3 ± 5.6 34.7 ± 4.8 0.2
ER [%] 36.2 ± 3.7 30.2 ± 4.0 < 0.0001*
LVWI [mm Hg × l/(min × m2)] 3.3 ± 1.0 3.7 ± 0.9 0.3
TFC [1/Ohm] 28.5 ± 3.3 36.0 ± 3.3 < 0.0001*
*Indicates significantly different results; all parameters are expressed as mean ± standard deviation, and p values
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and the renin–angiotensin systems [15, 16]. These results 
support the theory of increased sympathetic activity with 
those having obesity demonstrating an increased heart 
rate and increased peripheral vascular resistance. Un-
fortunately, the link between cardiac disease and obesity 
is complex, highlighted by the “obesity paradox” in which 
patients with obesity and established heart failure tend 
to have a more favorable prognosis than do lean subjects 
[17, 18]. Here, the complexity may arise from the intera-
ctions between renin and leptin both of which are increased 
in obesity and both of which can activate the sympathetic 
nervous system. Obesity may stimulate secretion by incre-
asing sodium chloride reabsorption in the loop of Henle, 
thereby reducing sodium chloride delivery to the macula 
densa. Leptin influences changes in the central nervous 
system by stimulating receptors in neurons of the arcuate 
nucleus of the hypothalamus and increasing the activity 
of the sympathetic nervous system. Moreover positive 
correlation was observed between the concentration of 
leptin in blood and with thickness of the wall and mass 
of the left ventricle of the heart, what is indicating for the 
participation of this hormone in the process of the excess 
of the left ventricle [19].
Activation of the sympathetic nervous system plays an 
important role in the hypertension associated with obesity. 
Risk estimates from the Framingham Heart Study suggest 
that 65% of cases of hypertension in women and 78% of 
cases in men can be attributed to obesity. Furthermore, 
an increase in body weight of about 4.5 kg is associated 
with an increase in systolic pressure about 4.5 mmHg. But 
even in the absence of any blood pressure alteration, obe-
sity is characterized by a marked sympathetic activation, 
possibly because of an impairment of reflex sympathetic 
restraint [20, 21].
Activation of the sympathetic nervous system can cau-
se hypertrophy of cardiac muscle and remodeling of the 
vascular walls. Interestingly, obesity is also associated with 
greater left ventricular mass, wall thickness and chamber 
size. It is also associated with sub-clinical, functional chan-
ges in left ventricle systolic function that can be detected 
by strain and strain rate imaging. These early abnormalities 
in left ventricle structure and function are associated with 
increased cardiovascular morbidity and mortality [22]. The 
results presented in this study demonstrate sub-clinical 
changes in cardiac function in a cohort of otherwise young 
and healthy males. These parameters which were derived 
non-invasively offer the potential to identify early cardiac 
changes, which could predict increased cardiovascular risk, 
although this would need confirming in a longitudinal study.
Thoracic fluid content is a noninvasive bioelectrical 
impedance measure of the electrical conductivity of the 
chest cavity. Thoracic fluid content is a reliable measure 
of chest fluid status and can identify small shifts in the 
thoracic content of fluid. In this study, BMI correlated 
inversely with the TFC, such that an increased body mass 
was associated with a reduced thoracic fluid content. This 
is of importance because recent studies have suggested 
that thoracic impedance may identify patients with heart 
failure risk even in the absence of clinical structural and 
functional abnormalities [23].
Conclusions
Parameters such as SV, CO, CI, TPRI, HI, ACI, TFC in the last 
decade has attracted much interest in clinical settings as di-
verse as heart failure management and critical care. These 
hemodynamic variables define arterial blood pressure level 
and their modification is helpful in the selection of phar-
macological therapy of hypertension. Reports from several 
clinical studies show that antihypertensive therapy based 
on hemodynamic measurements by cardiac impedance is 
more effective than recommendation based treatment in 
achieving blood pressure < 140/90 mm Hg [24–26].
Task Force® Monitor non-invasively measures changes 
in thoracic impedance generated by fluctuating blood volu-
mes during the cardiac cycle, allowing calculation of stroke 
volume, cardiac output and other derived parameters. Task 
Force® Monitor derived also cardiac index (CI) and systemic 
vascular resistance index can help determine how current 
therapy is impacting that patient from a hemodynamic 
perspective [24–26].
Obesity is associated with sub-clinical cardiac and 
cardiovascular abnormalities that can be identified using 
Figure 1. Reduced cardiac inotropy in the obesity; BMI — body 
mass index
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non-invasive measures. The differences identified in those 
with obesity were in young and healthy individuals. It will 
be important to determine whether these findings can be 
used to predict future clinical abnormalities.
Limitations
These findings may be limited by the relatively small size 
of the cohorts included. However, through the assessment 
of young and otherwise healthy males in the controlled 
environment of the cardiovascular laboratory the results 
demonstrated are reliable. As all the measurements are 
cross-sectional the study lacks the ability to assess risk of 
future events but does reveal important potential abnorma-
lities which require further longitudinal investigation. One 
advantage of the indices used in this study as that the ma-
jority can be corrected for body surface area, however, the 
measurement of thoracic fluid content is based on models 
which was derived from non-obese individuals and there-




Wprowadzenie. Liczba otyłych osób zwiększa się gwałtownie na całym świecie. W badaniach przeprowadzonych wśród 
otyłych dorosłych i dzieci potwierdzono, że zaburzenia funkcji układu sercowo-naczyniowego i autonomicznego układu 
nerwowego mogą wyjaśniać zwiększoną śmiertelność w tej grupie.
Materiał i metody. W badaniach przedstawiono analizę wartości hemodynamicznych, autonomicznych i sercowo-
-naczyniowych w kohorcie dobrze scharakteryzowanych, młodych mężczyzn z otyłością w porównaniu z mężczyznami 
w podobnym wieku bez otyłości. Do badania użyto systemu Task Force® Monitor.
Wyniki. W grupie osób z otyłością znacznie wyższe były wartości tętna (74,3 ± 11,8 v. 56,0 ± 8,9 n/min; p < 0,0001), 
ciśnienia skurczowego (128,1 ± 9,4 v. 114,3 ± 7,0 mm Hg; p < 0,0001) i rozkurczowego (85,1 ± 8,2 v. 70,7 ± 
± 6,2 mm Hg; p < 0,0001) niż w grupie osób bez otyłości. Ponadto wykazano obniżone wartości objętości wyrzutowej 
serca (81,3 ± 22,7 v. 112,8 ± 20,3 ml; p < 0,0001), pojemności minutowej (5,9 ± 1,5 v. 6,2 ± 1,4 l/min; p < 0,0001), 
zawartości płynu w klatce piersiowej (28,5 ± 3,3 v. 36,0 ± 3,3 1/Ohm; p < 0,0001), kurczliwości mięśnia sercowego 
(31,7 ± 12,9 v. 68,8 ± 16,1 1000/s; p < 0,0001) i wskaźnika Heather (0,1 ± 0,0 v. 0,3 ± 0,0 1/s2; p < 0,0001) w grupie 
osób z otyłością.
Wnioski. Badania autorów potwierdzają, że otyłość wiąże się z zaburzeniami funkcji układu sercowo-naczyniowego, któ-
re mogą zostać zidentyfikowane na podstawie nieinwazyjnych wskaźników. Wartości te mogą mieć istotne znaczenie kli-
niczne, aby przewidzieć, jakiego typu zmiany w obrębie układu sercowo-naczyniowego mogą wystąpić u osób z otyłością.
Słowa kluczowe: otyłość, funkcjonalnie pojedyncza komora, motoda Fontana, wrodzone wady serca, obrazowanie  
metodą Dopplera tkankowego, echokardiografia
Folia Cardiologica 2016; 11, 3: 171–177
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